RecruitingDeep Vein Thrombosis (DVT)Thrombus in the Peripheral Venous VasculatureVenous Embolism
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.
Sponsor: Argon Medical Devices
You may qualify if…
- ✓ Participants must meet all the following criteria to be eligible for the study:
- ✓ 1. At least 18 years of age at the time of consent.
- ✓ 2. Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body.
- ✓ 3. Written informed consent obtained through the IRB-approved ICF.
- ✓ For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:
- ✓ 4. Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:
- ✓ 1. Femoral-popliteal vein
- ✓ 2. Common femoral vein
You may not qualify if…
- ✕ Subjects will be excluded from the study if any of the following criteria are met:
- ✕ 1. Contraindication to systemic or therapeutic doses of anticoagulants.
- ✕ 2. Contraindication to iodinated contrast that cannot be adequately premedicated.
- ✕ 3. Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
- ✕ 4. Patients that are pregnant.
- ✕ 5. Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period.
- ✕ 6. Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure.
- ✕ 7. Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07102160 · last updated 2026-06-16